MHRA Approves New Batch Testing Standards for UK Medical Cannabis

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced updated batch testing standards for all Schedule 2 cannabis-based medicinal products (CBMPs) sold in the UK. The new requirements mandate independent third-party testing for THC and CBD concentration, terpene profiles, and microbiological safety. Medical cannabis manufacturers must now demonstrate batch-to-batch consistency within a 10% tolerance for cannabinoid content - down from the previous 15% allowance. Industry analysts expect this to raise the baseline quality of products available through licensed UK clinics. For patients, the changes mean greater confidence that their prescribed medication delivers consistent therapeutic effects. Specialist clinics have welcomed the move, noting that inconsistent product quality has been one of the most common patient concerns since the 2018 legalisation. The new standards take effect for all newly licensed products from Q3 2025, with existing products requiring compliance by Q1 2026. Companies failing to meet the new standards face suspension of their import licences.